The company said that reported sales for Q4 2025 rose 9.1% to $24,564 million, and that net earnings were $5,116 million. For the full year, reported sales rose 6.0% to $94,193 million, and net earnings were $26,804 million.

1. 01

   The company said that reported sales for Q4 2025 rose 9.1% to $24,564 million, and that net earnings were $5,116 million. For the full year, reported sales rose 6.0% to $94,193 million, and net earnings were $26,804 million.

2. 02

   Johnson & Johnson said diluted EPS for Q4 2025 was $2.10 and adjusted EPS was $2.46, while full-year 2025 EPS was $11.03 and adjusted EPS was $10.79. The company said both EPS and adjusted EPS included $(0.10) from the acquisition of Halda Therapeutics.

3. 03

   The company said Innovative Medicine sales for Q4 2025 rose 10.0% on a reported basis to $15,763 million, and MedTech sales rose 7.5% on a reported basis to $8,801 million. Worldwide adjusted operational growth was 6.1%.

4. 04

   The company presented estimated reported sales for full-year 2026 of $100.0B to $101.0B (midpoint $100.5B, or 6.7% at the midpoint), and adjusted EPS of $11.43 to $11.63 (midpoint $11.53, or 6.9% at the midpoint). These figures are illustrative calculations using a Euro Average Rate of January 2026 = $1.17.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.